You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

everolimus

( E-ver-OH-li-mus )
Funding:
Exceptional Access Program
  • everolimus - In combination with exemestane, for the treatment of hormone-receptor positive, HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
  • everolimus - Treatment of metastatic renal cell carcinoma (mRCC) as second or third line therapy in patients
    previously treated for mRCC with a funded tyrosine kinase inhibitor (TKI), with specific criteria
  • everolimus - For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (PNET), with specific criteria
  • everolimus - Treatment of unresectable, locally advanced or metastatic, well-differentiated non-functional neuroendocrine tumours (NETs) of GI or lung origin, according to clinical criteria
  • everolimus - Treatment of renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC), with specific criteria
  • everolimus - Treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex for whom surgical resection cannot be considered, with specific criteria
Other Name(s): Afinitor®
Appearance: tablet In various strengths

Patient Info Sheet

Dec 2017

What it is used for

For treating certain types of kidney and breast cancer, or other cancers which come from the pancreas, lung or stomach (neuroendocrine tumours).



You might also be interested in